Baseline characteristics of subjects treated in the phase 2 trial
| Characteristic . | Value (N = 28) . |
|---|---|
| Patient age, y | 67 (40-76) |
| Donor age, y | 25 (19-69) |
| Patient gender | |
| F | 12 (43) |
| M | 16 (57) |
| Race | |
| White | 28 (100) |
| Ethnicity | |
| Hispanic | 1 (4) |
| Non-Hispanic | 27 (96) |
| Disease | |
| AML | 13 (46) |
| CMML | 4 (14) |
| MDS | 9 (32) |
| MF | 2 (7) |
| KPS | |
| 80 | 9 (32) |
| 90 | 18 (64) |
| 100 | 1 (4) |
| HCT-CI | |
| 0-2 | 17 (61) |
| 3-4 | 11 (39) |
| Conditioning | |
| Bu(5300)/Flu | 7 (25) |
| Flu/Mel | 21 (75) |
| Donor type | |
| MRD | 7 (25) |
| MUD | 21 (75) |
| CMV (donor/recipient) | |
| Neg/neg | 4 (14) |
| Neg/pos | 8 (29) |
| Pos/neg | 6 (21) |
| Pos/pos | 10 (36) |
| Characteristic . | Value (N = 28) . |
|---|---|
| Patient age, y | 67 (40-76) |
| Donor age, y | 25 (19-69) |
| Patient gender | |
| F | 12 (43) |
| M | 16 (57) |
| Race | |
| White | 28 (100) |
| Ethnicity | |
| Hispanic | 1 (4) |
| Non-Hispanic | 27 (96) |
| Disease | |
| AML | 13 (46) |
| CMML | 4 (14) |
| MDS | 9 (32) |
| MF | 2 (7) |
| KPS | |
| 80 | 9 (32) |
| 90 | 18 (64) |
| 100 | 1 (4) |
| HCT-CI | |
| 0-2 | 17 (61) |
| 3-4 | 11 (39) |
| Conditioning | |
| Bu(5300)/Flu | 7 (25) |
| Flu/Mel | 21 (75) |
| Donor type | |
| MRD | 7 (25) |
| MUD | 21 (75) |
| CMV (donor/recipient) | |
| Neg/neg | 4 (14) |
| Neg/pos | 8 (29) |
| Pos/neg | 6 (21) |
| Pos/pos | 10 (36) |
Data are given as median (range) or number (percentage).
AML, acute myelogenous leukemia; Bu, busulfan; CMML, chronic myelomonocytic leukemia; CMV, cytomegalovirus; F, female; Flu, fludarabine; HCT-CI, transplant comorbidity index; KPS, Karnofsky performance status; M, male; MDS, myelodysplastic syndrome; Mel, melphalan; MF, myelofibrosis; MRD, matched related donor; MUD, matched unrelated donor; Neg, negative; Pos, positive.